Medical Device & Pharmaceutical Manufacturing Campus

Investment Overview

The subject property is a ±100,000 SF Medical Device & Pharmaceutical Manufacturing Campus situated on ±10.8 acres in Juncos, Puerto Rico. The campus comprises four (4) buildings — including ±30,000 SF of manufacturing space and three (3) ISO 8 cleanrooms totaling ±27,400 SF—together with an adjacent ±4.5-acre industrial-zoned parcel across PR-31 used for trailer parking and laydown. Developed and maintained to high operational standards by Becton Dickinson, the facility offers turnkey manufacturing infrastructure — with cleanroom environmental controls aligned to ISO Class 8 conditions — and substantial recent capital investment, including a $7M renovation of Building 20 (2019) and post-hurricane roof restorations across the campus.. Availability is phased, beginning in 2027, with sale-leaseback options available by building to align with a buyer’s occupancy timeline. The campus is offered for sale in its entirety, as a single fully integrated package — including the adjacent ±4.5-acre industrial parcel across PR-31. Its cleanroom infrastructure, redundant utilities, and strategic location make it an exceptional opportunity for medical device, pharmaceutical, biotech, or advanced manufacturing operations seeking to establish or expand in Puerto Rico.

Investment Highlights

• Location: PR-31, Ceiba Norte, Juncos, Puerto Rico 00777
• Total Building Area: ±100,000 SF across four (4) buildings
• Site Area: ±10.8 acres (incl. ±4.5 ac industrial land across PR-31)
• Manufacturing Space: ±30,000 SF
• Cleanrooms: Three (3) ISO 8 cleanrooms — ±27,400 SF total
• Recent Investment: Building 20 — $7M renovation (2019); campus roof restorations
• Power: 5,000 kVA substation; 2.5 MW Tier 4 primary generator (SCR emissions control); LUMA-connected
• Parking: 130 designated spaces + ±4.5-acre trailer/laydown parcel
• Zoning: Industrial
• Availability: Whole campus; phased occupancy beginning 2027
• Tier 4 Generator — advanced emissions controls, including urea-based Selective Catalytic Reduction (SCR), sharply reduce NOx and particulate emissions, aligning with stringent EPA requirements and strengthening the site’s environmental and sustainability posture.